SAN DIEGO, May 31, 2016 /PRNewswire/ -- Today, ChemDiv, a fully integrated target-to-market Contract Research Organization (CRO) headquartered in San Diego, announced that it has entered into a new drug discovery collaboration agreement with Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT). The agreement enables CFFT to use ChemDiv's unique chemistry platform to advance promising scientific research in the field of cystic fibrosis (CF) treatment. This collaboration allows ChemDiv to assist the largest CF clinical trials network in the world and contribute to the development of a lifelong cure for cystic fibrosis.
Cystic fibrosis is the most common autosomal disease, threatening the lives of its victims due to its progressive destruction of lungs. Patients frequently succumb to persistent lung infections as children or young adults. According to the Cystic Fibrosis Foundation, more than 70,000 people are living with the disease worldwide and approximately 1,000 new cases of CF are diagnosed in the U.S. alone each year.
ChemDiv is one of the industry's most experienced CROs and is a recognized global leader in discovery chemistry. ChemDiv has an exceptionally large, diverse, and pharmacologically-relevant library of molecules, with a commercial collection of over 1,600,000 individually crafted, lead-like, drug-like small molecules. According to the agreement, ChemDiv will provide discovery chemistry services to CFFT for their innovative research programs aimed at the development of lifesaving new therapies for cystic fibrosis.
"ChemDiv's unique drug discovery and evaluation platforms will provide CFFT with an excellent jumpstart for the identification of multiple novel therapeutic targets," said Nikolay Savchuk, CEO of ChemDiv. "We are proud to be a part of CFFT's exceptional research and development efforts to find a cure for this lethal genetic disease and save the lives of thousands of people around the globe."
ChemDiv is a recognized global leader in discovery chemistry with one of the industry's largest, most diverse, and most productive collections of over 1,600,000 individually crafted, lead-like, drug-like small molecules. Over the past 25 years the ChemDiv team has delivered hundreds of leads, drug candidates and new drug approvals in the areas of CNS, oncology, virology, inflammation, cardio and metabolic diseases to its pharma and biotech customers around the globe. ChemDiv's integrated drug discovery and evaluation platforms allow for an accelerated, cost-effective R&D process aimed at rapidly bringing a project from target ID to Phase 3 clinical candidate and beyond. http://www.chemdiv.com/
About Cystic Fibrosis Foundation Therapeutics, Inc.
Cystic Fibrosis Foundation Therapeutics, Inc. is the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation. Its purpose is to fund promising scientific research in academia, biotechnology and pharmaceutical industries to help accelerate the development of new CF treatments. CFFT conducts its own research, and also supports the Therapeutics Development Network - the largest CF clinical trials network in the world. https://www.cff.org/
About Cystic Fibrosis
Cystic fibrosis (CF) is one of the most common fatal genetic diseases affecting children and young adults. CF mainly affects the digestive system and lungs, causing persistent lung infections that lead to the destruction and loss of lung function, and eventually to death in the majority of CF patients.
SVP and General Manager
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/chemdiv-announces-new-drug-discovery-collaboration-agreement-with-cystic-fibrosis-foundation-therapeutics-inc-300276512.html